Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Accumulated Expenses (2016 - 2026)

Ironwood Pharmaceuticals' Other Accumulated Expenses history spans 16 years, with the latest figure at $9.4 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 112.92% to $9.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.4 million, a 112.92% increase, with the full-year FY2025 number at $9.4 million, up 112.92% from a year prior.
  • Other Accumulated Expenses hit $9.4 million in Q4 2025 for Ironwood Pharmaceuticals, up from $7.5 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for IRWD hit a ceiling of $14.3 million in Q3 2023 and a floor of $1.9 million in Q1 2021.
  • Historically, Other Accumulated Expenses has averaged $6.2 million across 5 years, with a median of $5.7 million in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: tumbled 55.11% in 2021 and later soared 257.5% in 2023.
  • Tracing IRWD's Other Accumulated Expenses over 5 years: stood at $3.4 million in 2021, then rose by 5.53% to $3.6 million in 2022, then surged by 72.71% to $6.2 million in 2023, then dropped by 28.71% to $4.4 million in 2024, then skyrocketed by 112.92% to $9.4 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for IRWD at $9.4 million in Q4 2025, $7.5 million in Q3 2025, and $5.2 million in Q2 2025.